Table 3 Clinical trials with CDK4/6 inhibitors in combination with IR
From: CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Cancer Type | Phase | Arm | n | Status | NCT |
|---|---|---|---|---|---|
HGG a, DIPGb, bithalamic HGG | I/II | Ribociclib + IR | 24 | Active, not recruiting | NCT02607124 |
Glioma (HGG, DIPG et al.) | I | Ribociclib + Everolimus + IR | 24 | Recruiting | NCT03355794 |
Locally advanced HNSCC | I/II | Palbociclib + Cetuximab + IMRT c | 33 | Recruiting | NCT03024489 |
HPV-unrelated HNSCC | II | Palbociclib + Cetuximab or Cisplatin + IMRT | 29 | Recruiting | NCT03389477 |
Bone metastatic breast cancer (HR+/HER2-) | II | Palbociclib + Hormone therapy + IR | 42 | Recruiting | NCT03691493 |
Metastatic breast cancer (HR+/HER2-) | II | Palbociclib + Letrozole ± SBRT d | 204 | Not yet recruiting | NCT04220476 |